Calliditas Therapeutics AB (publ)
CALT
NASDAQ
| 06/30/2024 | 03/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 84.19% | -33.06% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 84.19% | -33.06% | |||
| Cost of Revenue | 270.87% | -35.72% | |||
| Gross Profit | 74.89% | -32.93% | |||
| SG&A Expenses | 19.29% | 19.39% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 64.97% | -247.70% | |||
| Total Operating Expenses | 15.13% | 19.52% | |||
| Operating Income | 84.97% | -960.29% | |||
| Income Before Tax | 83.23% | -1,674.62% | |||
| Income Tax Expenses | 502.32% | -128.96% | |||
| Earnings from Continuing Operations | 81.25% | -1,270.89% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 81.25% | -1,270.89% | |||
| EBIT | 84.97% | -960.29% | |||
| EBITDA | 85.40% | -920.02% | |||
| EPS Basic | 81.26% | -1,270.19% | |||
| Normalized Basic EPS | 83.22% | -1,569.28% | |||
| EPS Diluted | 81.26% | -1,270.19% | |||
| Normalized Diluted EPS | 83.22% | -1,569.28% | |||
| Average Basic Shares Outstanding | 0.03% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.03% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
